Skip to content

How anxiety and body signals lead to binge eating in daily life

Physiological correlates of anxiety-driven binge eating in a naturalistic setting

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN24349737
Enrollment
120
Registered
2025-11-10
Start date
2024-12-15
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Binge-Eating Disorder (BED), Generalized Anxiety Disorder (GAD) Mental and Behavioural Disorders

Interventions

This study employed a prospective, observational longitudinal cohort design with four distinct arms: a comorbid Binge-Eating Disorder and Generalized Anxiety Disorder group (BED + GAD, n = 40), a BED-

Sponsors

Freie Universität Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18–55 years 2. Body mass index (BMI) between 18.5 and 40 kg/m² 3. Sufficient fluency in German to complete study procedures 4. Meeting DSM-5 diagnostic criteria for one of the four defined groups: 4.1. Comorbid Group (GAD+BED): Co-occurring Generalized Anxiety Disorder and Binge-Eating Disorder 4.2. BED Control Group (BED-only): Binge-Eating Disorder and no lifetime anxiety disorder 4.3. Anxiety Control Group (GAD-only): Generalized Anxiety Disorder and no lifetime eating disorder 4.4. Healthy Control Group (HC): No current or lifetime psychiatric diagnosis

Exclusion criteria

Exclusion criteria: 1. Current substance use disorder, psychosis, or neurological disease 2. Active suicidality 3. Pregnancy 4. Current use of medications known to influence cardiac or endocrine function (e.g., beta-blockers, corticosteroids)

Design outcomes

Primary

MeasureTime frame
1. Momentary urge to binge (measured on a 0-100 visual analogue scale 5 times daily during the 14-day ambulatory period) 2. Binge episode occurrence (binary yes/no from event-contingent reports during the 14-day ambulatory period)

Secondary

MeasureTime frame
1. Heart rate variability (Root Mean Square of Successive Differences [RMSSD] in milliseconds), measured continuously during the 14-day ambulatory period and in response to the laboratory stress test 2. Salivary cortisol level (nmol/L), measured at four fixed times daily during the 14-day period and in response to the laboratory stress test 3. Contextual/behavioral markers (location variance, screen time) derived from passive smartphone sensing during the 14-day period

Countries

Germany

Contacts

Public ContactYixuan Liang
yliang56@jh.edu+1 (0)4438388609

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026